RICHMOND, British Columbia, Feb. 19, 2009 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) today reported on its RECAF presentation at this international cancer congress held in Barcelona, Spain.
Four months ago, BioCurex, represented by Dr. Ricardo Moro, was invited to present results on its cancer marker RECAF at this prestigious meeting. The congress gathered close to 400 specialists in cancer markers worldwide, with the majority being from Europe, where cancer markers are extensively used and BioCurex holds issued patents.
This meeting is very focused on the clinical uses of tumor markers and it brings together physicians who use cancer markers, clinical chemists who carry out the tests and companies that develop or produce tests for cancer diagnosis. It is an ideal forum to present results on a novel cancer marker and as such, BioCurex's RECAF draw a great deal of attention.
Dr. Moro's presentation - in a plenary session - was very well received and as a result, two top clinical chemistry groups expressed an interest in developing collaborations with BioCurex to independently validate the usefulness of RECAF in the clinical environment as well as to further advance the research on this marker. The directors of these teams are members of the European Group on Tumor Markers, an institution heavily involved in creating the recommendations for the use of cancer markers in the European Union, which are also followed by other countries. These two scientists have published over 250 scientific papers on the use of cancer markers.
Dr. Moro stated: "We are very pleased with the interest elicited by our results. These collaborations translate into several important elements for BioCurex:
* They will work completely independently from BioCurex and therefore the data thus produced can be used for regulatory purposes not only in Europe, but also in America. * They will perform all the work at their expense with the exception of the cost of the tests, which BioCurex will initially provide free of cost. * The two groups evaluate and publish results for diagnostic products marketed by large diagnostic companies, including Abbott and Roche, and therefore their opinions and recommendations are important for companies working in the field. * Finally, since these scientists are leaders in the field; their independent validation of our results may prompt of other scientists to work with RECAF, which besides the obvious scientific impact could also become a source of revenue.
We are honored by their interest to work with us and we are looking forward to developing these collaborations in the near future, as well as continuing the ones that we have already established."
For more information on the XII International Symposium on Biology and Clinical Usefulness of Tumor Markers visit http://www.oncolab.net/informationingle09.html
For information on the European Group on Tumor Markers, visit http://egtm.eu/
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements see: http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt).
The cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.